Research programme: cancer therapeutics - Eleven Biotherapeutics

Drug Profile

Research programme: cancer therapeutics - Eleven Biotherapeutics

Alternative Names: Armed Antibodies™; NP-1 - Eleven Biotherapeutics; VB 4011; VB 6901; VB-6008; VB-6011; VB-6050; VB-7756; VB1-008; VB1-050; VBX-008; VBX-011; VBX-050

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator Viventia Biotechnologies
  • Developer Eleven Biotherapeutics
  • Class Antineoplastics; Immunoconjugates; Peptides; Recombinant fusion proteins
  • Mechanism of Action CD44 antigen modulators; Epithelial cell adhesion molecule modulators; Protein synthesis inhibitors; Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Sep 2016 Viventia Biotechnologies has been acquired and merged into Eleven Biotherapeutics
  • 16 Apr 2016 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research
  • 10 Jun 2015 Preclinical development is ongoing in Canada for VB 6011, VB 6008 and VB 6756 (Viventia Biotechnologies pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top